Page 2119 - Williams Hematology ( PDFDrive )

2094 Part XII: Hemostasis and Thrombosis Chapter 121: Acquired Qualitative Platelet Disorders 2095

461. Peterson P, Hayes TE, Arkin CF, et al: The preoperative bleeding time test lacks clinical 495. Wiedmer T, Ando B, Sims PJ: Complement C5b-9-stimulated platelet secretion is
benefit. Arch Surg 133:134–139, 1998. associated with a calcium-initiated activation of cellular protein kinases. J Biol Chem
462. Stewart JH, Castaldi PA: Uraemic bleeding: A reversible platelet defect corrected by 262:13674, 1987.
dialysis. Q J Med 36(143):409–423, 1967. 496. Warkentin TE: Heparin-induced thrombocytopenia: Pathogenesis and management.
463. Lindsay RM, Friesen M, Koens F, et al: Platelet function in patients on long-term peri- Br J Haematol 121(4):535–555, 2003.
toneal dialysis. Clin Nephrol 6:335–339, 1976. 497. Lechner K, Pabinger I, Obermeier HL, Knoebl P: Immune-mediated disorders caus-
464. Weigert AL, Schafer AI: Uremic bleeding: Pathogenesis and therapy. Am J Med Sci ing bleeding or thrombosis in lymphoproliferative diseases. Semin Thromb Hemost
316:94–104, 1998. 40(3):359–370, 2014.
465. Vigano G, Benigni A, Mendogni D, et al: Recombinant human erythropoietin to cor- 498. Giannini S, Mezzasoma AM, Guglielmini G, et al: A new case of acquired Glanz-
rect uremic bleeding. Am J Kidney Dis 18:44–49, 1991. mann’s thrombasthenia: Diagnostic value of flow cytometry. Cytometry B Clin Cytom
466. Tassies D, Reventer JC, Cases A, et al: Effect of recombinant human erythropoietin 74(3):194–199, 2008.
treatment on circulating reticulated platelets in uremic patients: Association with early 499. Kannan M, Chatterjee T, Ahmad F, et al: Acquired Glanzmann’s thrombasthenia asso-
improvement in platelet function. Am J Hematol 59(2):105–109, 1998. ciated with hairy cell leukaemia. Eur J Clin Invest 39(12):1110–1111, 2009.
467. Mannucci PM: Desmopressin: A non-transfusional form of treatment for congenital 500. Lackner H, Karpatkin S: On the “easy bruising” syndrome with normal platelet count:
and acquired bleeding disorders. Blood 72:1449, 1988. A study of 75 patients. Ann Intern Med 83(2):190–196, 1975.
468. Rose EH, Aledort LM: Nasal spray desmopressin (DDAVP) for mild hemophilia A and 501. Clancy R, Jenkins E, Firkin B: Qualitative platelet abnormalities in idopathic thrombo-
von Willebrand disease. Ann Intern Med 114:563, 1991. cytopenic purpura. N Engl J Med 286:622, 1972.
469. Canavese C, Salomone M, Pacitti A, et al: Reduced response of uraemic bleeding time 502. Heyns DA, Fraser J, Retief FP: Platelet aggregation in chronic idiopathic thrombocy-
to repeated doses of desmopressin. Lancet 1:867, 1985. topenic purpura. J Clin Pathol 31:1239, 1978.
470. Byrnes JJ, Larcada A, Moake JL: Thrombosis following desmopressin for uremic bleed- 503. Regan MG, Lackner H, Karpatkin S: Platelet function and coagulation profile in lupus
ing. Am J Hematol 28:63, 1988. erythematosus. Am J Med 81:462, 1974.
471. Mannucci PM, Lusher JM: Desmopressin and thrombosis. Lancet 2(8664):675–676, 1989. 504. Dorsch CA, Meyerhoff J: Mechanisms of abnormal platelet aggregation in systemic
472. Liu YK, Kosfeld RE, Marcum SG: Treatment of uremic bleeding with conjugated estro- lupus erythematosus. Arthritis Rheum 25:966, 1982.
gen. Lancet 2(8408):887–890, 1984. 505. Meyerhoff J, Dorsch CA: Decreased platelet serotonin levels in systemic lupus erythe-
473. Vigano G, Gaspari F, Locatelli M, et al: Dose-effect and pharmacokinetics of estrogens matosus. Arthritis Rheum 24:1495, 1981.
given to correct bleeding time in uremia. Kidney Int 34:853–858, 1988. 506. Stuart MJ, Kelton JG, Allen JB: Abnormal platelet function and arachidonate metabo-
474. Heistinger M, Stockenhuber F, Schneider B, et al: Effect of conjugated estrogens on lism in chronic idiopathic thrombocytopenic purpura. Blood 58:326, 1981.
platelet function and prostacyclin generation in CRF. Kidney Int 38:1181–1186, 1990. 507. Harker LA, Malpass TW, Branson HE, et al: Mechanism of abnormal bleeding in
475. Bronner MH, Pate MD, Cunningham JT, Marsh WH: Estrogen-progesterone therapy patients undergoing cardiopulmonary bypass: Acquired transient platelet dysfunction
for bleeding of gastrointestinal telangiectasias in chronic renal failure. Ann Intern Med associated with selective alpha-granule release. Blood 56:824–834, 1975, 1980.
105(3):371–374, 1986. 508. Woodman RC, Harker LA: Bleeding complications associated with cardiopulmonary
476. Vigano G, Zoja C, Corna D, et al: 17 Beta-estradiol is the most active component of the bypass. Blood 76:1680–1697, 1990.
conjugated estrogen mixture active on uremic bleeding by a receptor mechanism. Mol 509. Mammen EF, Koets MH, Washington BC, et al: Hemostasis changes during cardiopul-
Pharmacol 252(1):344–348, 1990. monary bypass surgery. Semin Thromb Hemost 11:281, 1985.
477. Triulzi DJ, Blumber N: Variability in response to cryoprecipitate treatment for hemo- 510. Khuri SF, Wolfe JA, Josa M, et al: Hematologic changes during and after cardiopulmo-
static defects in uremia. Yale J Biol Med 63:1–7, 1990. nary bypass and their relationship to the bleeding time and nonsurgical blood loss.
478. Thompson AR, Harker LA: Approach to bleeding disorders, in Manual of Hemostasis J Thorac Cardiovasc Surg 104:94–107, 1992.
and Thrombosis, 3rd ed, pp 57–64. FA Davis, Philadelphia, 1983. 511. Martin JF, Daniel TD, Trowbridge EA: Acute and chronic changes in platelet volume
479. Bloor AJ, Smith GA, Jaswon M, et al: Acquired thrombasthenia due to GPIIbIIIa plate- and count after cardiopulmonary bypass induced thrombocytopenia in man. Thromb
let autoantibodies in a 4-yr-old child. Eur J Haematol 76(1):89–90, 2006. Haemost 57(1):55–58, 1987.
480. Porcelijn L, Huiskes E, Maatman R, et al: Acquired Glanzmann’s thrombasthenia 512. Chandler AB, Hutson MS: Platelet plug formation in an extracorporeal unit. Am J Clin
caused by glycoprotein IIb/IIIa autoantibodies of the immunoglobulin G (IgG ), IgG 2 Pathol 64(1):101–107, 1975.
1
1
or IgG subclass: A study in six cases. Vox Sang 95(4):324–330, 2008. 513. Lindon JN, McManama, Kushner L: Does the conformation of adsorbed fibrinogen
4
481. Blickstein D, Dardik R, Rosenthal E, et al: Acquired thrombasthenia due to inhibitory dictate platelet interactions with artificial surfaces? Blood 68:355, 1986.
effect of glycoprotein IIbIIIa autoantibodies. Isr Med Assoc J 16(5):307–310, 2014. 514. Singer RL, Mannion JD, Bauer TL, Armenti FR, Edie RN: Complications from
482. Solh M, Mescher C, Klappa A, et al: Acquired Glanzmann’s thrombasthenia with opti- heparin-induced thrombocytopenia in patients undergoing cardiopulmonary bypass.
mal response to rituximab therapy. Am J Hematol 86(8):715–716, 2011. Chest 104(5):1436–1440, 1993.
483. George JN, Woolf SH, Raskob GE, et al: Idiopathic thrombocytopenic purpura: A prac- 515. Pouplard C, Leroux D, Rollin J, et al: Incidence of antibodies to protamine sulfate/hep-
tice guideline developed by explicit methods for the American Society of Hematology. arin complexes incardiac surgery patients and impact on platelet activation and clinical
Blood 88(1):3–40, 1996. outcome. Thromb Haemost 109(6):1141–1147, 2013.
484. George JN, El-Harake MA, Raskob GE: Chronic idiopathic thrombocytopenic pur- 516. Bakchoul T, Zollner H, Amiral J, et al: Anti-protamine-heparin antibodies: Incidence,
pura. N Engl J Med 331:1207–1215, 1994. clinical relevance, and pathogenesis. Blood 121(15):2821–2827, 2013.
485. McMillan R: Antiplatelet antibodies in chronic adult immune thrombocytopenic pur- 517. Panzer S, Schiferer A, Steinlechner B, et al: Serological features of antibodies to protamine
pura: Assays and epitopes. J Pediatr Hematol Oncol 25 Suppl 1:S57–S61, 2003. inducing thrombocytopenia and thrombosis. Clin Chem Lab Med 53(2):249–255, 2015.
486. Meyer M, Kirchmaier CM, Schirmer A, et al: Acquired disorder of platelet function 518. Bick RL: Hemostasis defects associated with cardiac surgery, prosthetic devices, and
associated with autoantibodies against membrane glycoprotein IIb-IIIa complex-1. other extracorporeal circuits. Semin Thromb Hemost 11(3):249–280, 1985.
Glycoprotein analysis. Thromb Haemost 65:491–496, 1991. 519. Bachmann F, McKenna R, Cole ER, Najafi H: The hemostatic mechanism after open
487. Balduini CL, Grignani G, Sinigaglia F, et al: Severe platelet dysfunction in a patient with heart surgery. I. Studies on plasma coagulation factors and fibrinolysis in 512 patients
autoantibodies against membrane glycoproteins IIb-IIIa. Haemostasis 7:98–104, 1987. after extracorporeal circulation. J Thorac Cardiovasc Surg 70:76, 1975.
488. Balduini CL, Bertolino G, Noris P, et al: Defect of platelet aggregation and adhesion 520. Beurling-Harbury C, Galvan CA: Acquired decrease in platelet secretory ADP associ-
induced by autoantibodies against platelet glycoprotein IIIa. Thromb Haemost 68:208– ated with increased post-operative bleeding in post-cardiopulmonary bypass patients
213, 1992. and in patients with severe valvular heart disease. Blood 52:13, 1978.
489. Fuse I, Higuchi W, Narita M, et al: Overproduction of antiplatelet antibody against gly- 521. Abrams CS, Ellison N, Budzynski AZ, Shattil S: Direct detection of activated platelets
coprotein IIb after splenectomy in a patient with Evans syndrome resulting in acquired and platelet-derived microparticles in humans. Blood 75:128–138, 1990.
thrombasthenia [see comments]. Acta Haematol 99(2):83–88, 1998. 522. Nannizzi-Alaimo L, Rubenstein MH, Alves VL, et al: Cardiopulmonary bypass induces
490. Stricker RB, Wong D, Saks SR, et al: Acquired Bernard-Soulier syndrome: Evidence for release of soluble CD40 ligand. Circulation 105(24):2849–2854, 2002.
the role of a 210,000-molecular weight protein in the interaction of platelets with von 523. Wahba A, Rothe G, Lodes H, et al: The influence of the duration of cardiopulmonary
Willebrand factor. J Clin Invest 76:1274–1278, 1985. bypass on coagulation, fibrinolysis and platelet function. Thorac Cardiovasc Surg
491. Devine DV, Currie MS, Rosse WF, Greenberg CS: Pseudo-Bernard-Soulier syndrome: 49(3):153–156, 2001.
Thrombocytopenia caused by autoantibody to platelet glycoprotein Ib. Blood 70:428– 524. George JN, Pickett EB, Saucerman S, et al: Platelet surface glycoproteins. Studies on
431, 1987. resting and activated platelets and platelet membrane microparticles in normal sub-
492. Deckmyn H, Zhang J, Van Houtte E, Vermylen J: Production and nucleotide sequence jects, and observations in patients during adult respiratory distress syndrome and car-
of an inhibitory human IgM autoantibody directed against platelet glycoprotein Ia/IIa. diac surgery. J Clin Invest 78(2):340–348, 1986.
Blood 84(6):1968–1974, 1994. 525. Gluszko P, Ricinski B, Musial J, et.al. Fibrinogen receptors in platelet adhesion to sur-
493. Dromigny A, Triadou P, Lesavre P, et al: Lack of platelet response to collagen associated faces of extracorporeal circuit. Am J Physiol 252:H615, 1987.
with autoantibodies against glycoprotein (GP) Ia/IIa and Ib/IX leading to the discovery 526. van den Dengen JJ, Karliczek GF, Brenken U, et al: Clinical study of blood trauma
of SLE. Hematol Cell Ther 38(4):355–357, 1996. during perfusion with membrane and bubble oxygenators. J Thorac Cardiovasc Surg
494. Boylan B, Chen H, Rathore V, et al: Anti-GPVI-associated ITP: An acquired platelet 83(1):108–116, 1982.
disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain 527. Edmunds LH Jr, Colman RW: Thrombin during cardiopulmonary bypass. Ann Thorac
complex from the human platelet surface. Blood 104(5):1350–1355, 2004. Surg 82(6):2315–2322, 2006.

Kaushansky_chapter 121_p2073-2096.indd 2094 9/18/15 10:28 AM